Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Electrophysiological features of acute inflammatory demyelinating polyneuropathy associated with SARS-CoV-2 infection

Antonino Uncini a,*, Camillo Foresti b, Barbara Frigeni b, Benedetta Storti b, Maria Cristina Servalli b, Stefano Gazzina c, Giuseppe Cosentino d, Francesca Bianchi e, Ubaldo Del Carro e, Enrico Alfonsi f, Stefano Cotti Piccinelli g, Giovanni De Maria c, Alessandro Padovani g, Massimiliano Filosto g, Luigi Ippoliti h

a Department of Neuroscience, Imaging and Clinical Sciences, University “G. d’Annunzio”, Chieti, Italy
b Neuropathophysiology, “Papa Giovanni XXIII” Hospital, Bergamo, Italy
c Neuropathophysiology, ASST Spedali Civili, Brescia, Italy
d Department of Brain and Behavioral Sciences, University of Pavia and IRCCS Mondino Foundation, Pavia, Italy
e Neurology and Neurophysiology Unit, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Milano, Italy
f IRCCS Mondino Foundation, Pavia, Italy
g Center for Neuromuscular Diseases, Unit of Neurology, ASST Spedali Civili and University of Brescia, Brescia, Italy
h Statistics Unit, Department of Economics, University “G. d’Annunzio”, Pescara, Italy

Received 10 November 2020; accepted 12 February 2021
Available online 18 February 2021

KEYWORDS
Acute inflammatory demyelinating polyradiculoneuropathy;
Critical illness myopathy;

Summary
Objective. — To assess whether patients with acute inflammatory demyelinating polyneuropathy (AIDP) associated with SARS-CoV-2 show characteristic electrophysiological features.
Methods. — Clinical and electrophysiological findings of 24 patients with SARS-CoV-2 infection and AIDP (S-AIDP) and of 48 control AIDP (C-AIDP) without SARS-CoV-2 infection were compared.
Results. — S-AIDP patients more frequently developed respiratory failure (83.3% vs. 25%, P = 0.000) and required intensive care unit (ICU) hospitalization (58.3% vs. 31.3%, P = 0.000).

* Corresponding author at: Department of Neuroscience, Imaging and Clinical Sciences, University “G. d’Annunzio”, Via Luigi Polacchi 11, 66100 Chieti, Italy.
E-mail address: uncini@unich.it (A. Uncini).

https://doi.org/10.1016/j.neucli.2021.02.001
0987-7053/© 2021 Elsevier Masson SAS. All rights reserved.
In C-AIDP, distal motor latencies (DMLs) were more frequently prolonged (70.9% vs. 26.2%, \( P=0.000 \)) whereas in S-AIDP distal compound muscle action potential (dCMAP) durations were more frequently increased (49.5% vs. 32.4%, \( P=0.002 \)) and F waves were more often absent (45.6% vs. 31.8%, \( P=0.011 \)). Presence of nerves with increased dCMAP duration and normal or slightly prolonged DML was elevenfold higher in S-AIDP (31.1% vs. 2.8%, \( P=0.000 \)); 11 S-AIDP patients showed this pattern in 2 nerves.

**Conclusion.** — Increased dCMAP duration, thought to be a marker of acquired demyelination, can also be observed in critical illness myopathy. In S-AIDP patients, an increased dCMAP duration dissociated from prolonged DML, suggests additional muscle fiber conduction slowing, possibly due to a COVID-19-related hyperinflammatory state. Absent F waves, at least in some S-AIDP patients, may reflect α-motor neuron hypoexcitability because of immobilization during the ICU stay. These features should be considered in the electrophdiagnosis of SARS-CoV-2 patients with weakness, to avoid misdiagnosis.

© 2021 Elsevier Masson SAS. All rights reserved.
Sensory studies were performed antidromically in median, ulnar and sural nerves and amplitude of sensory nerve action potential (SNAP) was measured from baseline to negative peak.

The criteria set used here for electrodiagnosis of GBS subtypes was originally devised on the basis of two serial electrophysiological studies but also showed highest diagnostic accuracy in the first study compared with two other criteria sets, in a cohort with a balanced number of AIDP and axonal GBS patients. This approach has already been employed in the electrodiagnosis of GBS associated with Zika virus infection (table, supplementary material) [22,23]. This criterion set is mainly characterized by the following features: (1) cut-off values for demyelination are quite stringent (DML > 130% ULN, motor CV < 70% LLN); (2) duration of dCMAP is evaluated because it has been shown that increased duration is a sensitive and specific indicator of acquired demyelination [2,16]; (3) because of the recognition that conduction failure (even completely reversible) can be an expression of axonal pathology, p/d CMAP amplitude ratio < 0.7 is considered only for axonal GBS subtypes, whereas an increased (> 130%) p/d CMAP duration is considered indicative of demyelination [22,24]; (4) isolated F-wave absence, defined as unrecordable or markedly reduced persistence (< 20%) of F wave with otherwise normal conduction, is introduced as a parameter suggestive of axonal pathology [12,22]; (5) sural sparing, defined as abnormal ulnar and normal sural SNAP amplitude, is also taken into account [3].

Statistical methods

The clinical characteristics and electrophysiological data between the two groups were compared using standard (unpaired) statistical t-test procedures to assess differences between means and proportions [9]. For the electrophysiological parameters in which the samples were small we also employed permutation tests to compare the mean of two populations [15]. Because of their flexibility and minimal assumptions, results from this non-parametric approach are compared with the standard statistical t-test which requires more restrictive distributional assumptions for the data. For statistical comparisons we considered the following test specifications: (1) the null hypothesis represents the "no difference" situation and the alternative represents an "upper tailed" specification, i.e. it is assumed that the mean/proportion in the C-AIDP group is greater than the mean/proportion of S-AIDP; (2) the null hypothesis represents the "no difference" situation and the alternative represents a "lower tailed" specification, i.e. it is assumed that the mean/proportion in the C-AIDP group is smaller than the mean/proportion of S-AIDP; (3) no upper or lower tailed version of the test is assumed and we simply assume that the population means are different. Finally, as for test interpretation, when the two-sided P-value is less than the conventional 0.05 the conclusion is that there is a significant difference between the means/proportions. Similarly, values smaller than 0.05 for the one-sided test, also represent statistically significant results.

Ethical committee and informed consent

This study is part of a project approved by Ethical Committee of the University and Spedali Civili of Brescia. All C-AIDP patients provided informed signed consent for the utilization of personal data for research purposes. Regarding the S-AIDP patients, given the difficulty in systematically obtaining informed consent and given the public interest of the project, the research was conducted in the context of the authorizations guaranteed by Article 89 of the GDPR EU Regulation 2016/679.

Results

Patients and clinical features

The data set consisted of 24 S-AIDP and 48 C-AIDP patients. The demographic and clinical characteristics are reported in Table 1. The S-AIDP group consisted of 7 females (age: median 69 years, [IQR 51–74.8], range 42–81) and 17 males (age: median 58 years, [IQR 49–62.3], range 35–76). The control group was composed of 21 females (age: median 56 years [IQR 36.8–64.8], range 16–80) and 27 males (age: median 49, [IQR 28.5–58.5], range 13–74). The median age between the two groups was not significantly different (Kruskal-Wallis test P = 0.19). Three S-AIDP patients had type-2 diabetes and arterial hypertension; five additional patients had arterial hypertension. Three C-AIDP patients had type-2 diabetes and arterial hypertension, two had only diabetes and four only arterial hypertension. The diagnosis of SARS-CoV-2 infection was made by positive RT-PCR of nasopharyngeal swab in 83.3% patients and by serology in 16.7%. Most frequent presenting symptoms of COVID-19 were fever (70.8%), cough (70.8%) and dyspnea (58.3%). Hypo-agueusia and hypo-anosmia were reported in 33% and 29.2% of patients, respectively. Interstitial pneumonia was documented by chest RX or CT in 79.2% of patients. In all S-AIDP patients the neuropsychiatric symptoms followed the onset of COVID-19 with a median interval of 28.5 days. All S-AIDP and C-AIDP patients had the classical GBS sensorimotor form with ascending weakness and hypo-areflexia [26]. Cranial nerves were involved in 14 (58.3%) patients. Oculo-motor nerves were involved in one patient, facial nerve was involved in ten patients (in seven bilaterally), bulbar nerves were involved in 7 patients. Antibodies to gangliosides GM1, GD1a, GD1b and GQ1b were searched in 11 (45.8%) patients and were negative in all.

Significantly more C-AIDP patients fulfilled the Brighton level 1 of diagnostic certainty. This difference was due to the fact that CSF examination was performed in all C-AIDP patients whereas it was performed in only 15 (62.5%) S-AIDP patients. In the remaining nine patients CSF was not examined because of anticoagulant therapy or because of difficulties connected with the ongoing severe health emergency. However, considering that all patients of both groups belonged to the Brighton level 1 or 2 the overall diagnostic certainty is fairly high.

Twenty (83.3%) S-AIDP and 12 (25%) C-AIDP patients developed respiratory failure. Fourteen (58.3%) S-AIDP and 15 (31.3%) C-AIDP were admitted to the intensive care unit (ICU).
Electrophysiological findings

The median interval between GBS onset and the electrophysiological test in 21 S-AIDP patient was 7 days, [IQR 6–11], range 3–21. In three patients it was not possible to establish with certainty when the neuropathic symptoms developed. In C-AIDP the median interval between the GBS onset and the electrophysiological test was 10 days, [IQR 6–11.5], range 2–20. The intervals were not significantly different (P = 0.73).

In S-AIDP patients a total of 103 motor nerves (mean 4.3 per patient) were studied, 6 peroneal nerves were unexcitable. In C-AIDP a total of 179 motor nerves (mean 3.7 per patient) were studied, 9 peroneal and two tibial nerves were unexcitable.

Table 2 shows the descriptive statistics of five electrophysiological parameters measured in median, ulnar, peroneal and tibial nerves of both groups. In the S-AIDP group, only six median nerves were studied and in all of them F waves were not recordable; comparison with the median nerves of C-AIDP showed no significant differences for all the electrophysiological parameters even employing the permutation test. In ulnar, peroneal, and tibial nerves, the mean dCMAP amplitudes were not significantly different in the two groups. Mean DMLs were significantly more prolonged in the ulnar, tibial and peroneal nerves of C-AIDP whereas in S-AIDP, mean dCMAP durations were significantly increased in the ulnar nerve at the level of 5% and in the tibial at 10% level. Regarding the other parameters, the mean values of CV was significantly lower in C-AIDP ulnar nerves and higher in the peroneal nerves. Mean minimal F latency was significantly prolonged in tibial nerves of S-AIDP. Overall the results from the permutation test were consistent with the t-test in the case of large samples and provided robust results in cases of small samples. Table 3 shows the occurrence of abnormal motor conduction parameters, according to the cut-offs of the electrodagnostic criteria set employed, in the nerves of the two groups. Apart from the prevalence of decreased CV, the statistical test strongly indicates that the proportion of nerves with abnormal parameters is significantly different in the two cohorts. Specifically, the presence of nerves with prolonged minimal F wave was significantly higher in C-AIDP whereas nerves with no recordable F wave were more frequently observed in S-AIDP. DML was more frequently prolonged in C-AIDP whereas dCMAP duration was more often increased in S-AIDP. When we examined the relationship between DML and dCMAP duration in the individual nerves, the proportion of nerves that presented both prolonged DML and increased dCMAP duration was higher in the C-AIDP nerves. Interestingly, dCMAP duration was prolonged in the presence of normal or slightly increased (not reaching the cut-offs for demyelination) DML at a much higher percentage in S-AIDP nerves (Fig. 1B–D), whereas prolonged DML in the presence of normal or slightly increased (not reaching the cut-offs for demyelination) dCMAP duration was more frequent in C-AIDP. Thirty-two S-AIDP nerves presented normal or slightly prolonged DML in the presence of an increased dCMAP duration (mean: 14.0 ms ± 4.17, range 9.5–28.6 ms) and 11 S-AIDP patients (45.8%) had this pattern in at least two nerves. Regarding sensory conduction, 30 ulnar and 37 sural nerves were studied in S-AIDP and 47 ulnar and 46 sural nerves in C-AIDP cohort. The mean amplitude of ulnar SNAP was significantly lower, and the frequency of abnormal ulnar SNAPs (reduced amplitude or not recordable) was higher in the C-AIDP group. Conversely, the mean amplitude of sural SNAP and the frequency of abnormal sural SNAPs were comparable in the two groups (Table 4). Consequently sural sparing was more frequent in C-AIDP than in S-AIDP. Concentric needle EMG of at least one proximal and distal muscle was performed in 21 (87.5%) S-AIDP patients. Variable degrees of spontaneous activity (fibrillation potential and positive sharp waves) at rest were found in at least one muscles in 8 (38.1%) patients. The voluntary activity was impossible to evaluate in four patients hospitalized in ICU.

| Table 1 | Demographic and clinical characteristics of patients with AIDP and SARS-CoV-2 infection (S-AIDP) and of control AIDP (C-AIDP). |
|---------|--------------------------------------------------------------------------------------------------|
|          | S-AIDP                                                                                           | C-AIDP                                                                                           | P        |
| Gender   | 24 patients (17 M (71%))                                                                            | 48 patients (27 M (56%))                                                                            |         |
| Age (median years, [IQR], range)       | 59, [49–70], 35–81                                                                                | 50 [32–64], 13–80                                                                                | 0.19     |
| Diagnosis of SARS-CoV-2 infection | NPS                                                                                              | NA                                                                                               |         |
| Age (median years, [IQR], range)       | 7 F (29%)                                                                                         | 21 F (44%)                                                                                       |         |
| Interstitial pneumonia                  | Serology                                                                                         | NA                                                                                               |         |
| Age (median years, [IQR], range)       | 19 (79.2)                                                                                         | NA                                                                                               |         |
| Interval between onset of COVID-19 and | GBS symptoms (median days, [IQR], range)                                                         | NA                                                                                               |         |
| Brighton criteria                       | Brighton criteria                                                                                 |                                                   | 0.009*   |
| Level 1                               | 7 (29.2)                                                                                         | 30 (62.5)                                                                                       | 0.009*   |
| Level 2                               | 17 (70.8)                                                                                        | 18 (37.5)                                                                                        | 0.031*   |
| Respiratory failure                    | 20 (83.3)                                                                                        | 12 (25)                                                                                         | 0.000*   |
| ICU admission                          | 14 (58.3)                                                                                        | 15 (31.3)                                                                                       | 0.000*   |

ICU, intensive care unit; NA, not applicable; NPS, nasopharyngeal swab.
Table 2  Motor conduction findings in AIDP patients with SARS-CoV-2 infection (S-AIDP) and in control AIDP (C-AIDP) patients.

|                | DML         | CV         | dCMAP amplitude | dCMAP duration | F latency |
|----------------|-------------|------------|-----------------|----------------|-----------|
|                | Mean SD Min Max | No Mean SD Min Max | No Mean SD Min Max | No Mean SD Min Max | No SD SD Min Max |
| Ul n S-AIDP   | 3.6 1.4 2.2 8.8 | 31 51.9 11.0 25.1 69.2 | 31 4.5 2.8 0.8 9.5 | 31 10.7 4.7 5.0 26.0 | 31 36.9 8.9 30.1 59.4 | 18 |
| Ul n C-AIDP   | 5.2 2.8 2.8 22.0 | 48 46.7 9.9 17.0 61.0 | 48 4.5 2.9 0.6 12.4 | 48 8.9 2.8 5.3 19.3 | 47 38.1 8.3 26.6 64.0 | 29 |
| P Perm. test  | 0.003*       | 0.000*     | 0.031*          | 0.035*         | 0.989      | 0.021*     | 0.025*         | 0.635     | 0.638     | No |
| Tib S-AIDP    | 6.2 3.5 3.4 20.7 | 41 38.0 10.8 6.9 56.0 | 39 3.3 3.0 0.3 12.1 | 41 13.0 10.1 4.4 58.0 | 41 68.9 10.9 57.0 89.3 | 6 |
| Tib-C-AIDP    | 9.4 5.8 3.5 34.0 | 33 38.3 9.6 20.0 67.0 | 31 3.3 2.7 0.1 10.1 | 33 9.8 9.1 4.7 57.1 | 32 48.7 4.6 43.9 54.6 | 6 |
| P Perm. test  | 0.002*       | 0.002*     | 0.911           | 0.913          | 0.973      | 0.974      | 0.088**        | 0.083**   | 0.000*    | 0.002*    | No |
| Per S-AIDP    | 7.7 2.5 3.7 12.6 | 16 34.4 5.6 27.0 43.4 | 13 2.2 1.9 0.2 6.3 | 16 11.4 4.7 5.4 19.3 | 16 64.2 10.8 56.5 71.8 | 2 |
| Per C-AIDP    | 10.8 4.5 5.8 25.5 | 39 39.5 7.3 26.0 55.0 | 38 1.9 1.6 0.2 6.1 | 39 10.7 5.9 4.8 35.2 | 39 60.7 9.4 50.7 80.0 | 12 |
| P Perm. test  | 0.003*       | 0.006*     | 0.028*          | 0.025*         | 0.473      | 0.470      | 0.332           | 0.753     | 0.643     | No |
| Med S-AIDP    | 10.0 4.9 5.9 18.9 | 6 40.8 12.4 17.9 50.0 | 6 2.1 1.2 0.6 3.5 | 6 10.4 3.1 7.1 15.0 | 6 — — — — | — |
| Med C-AIDP    | 10.6 4.8 4.10 22.3 | 48 43.7 11.3 19.0 66.0 | 48 3.4 2.8 0.1 12.1 | 48 10.3 5.0 5.8 36.0 | 47 41.3 10.2 24.5 64.0 | 32 |
| P Perm. test  | 0.403        | 0.390      | 0.565           | 0.556          | 0.264      | 0.267      | 0.395           | 0.490     | —         | — |

CV, conduction velocity; dCMAP, distal compound muscle action potential; DML, distal motor latency; No, number of nerves; Perm, permutation; Ul n, ulnar; Tib, tibial; Per, peroneal; Med, Median.
* Significant at the 5% level.
** Significant at the 10% level.
because of sedation or coma. In the remaining 17 patients the recruitment pattern was reduced and at a qualitative evaluation the amplitude of motor unit action potentials (MUAPs) was described as reduced with an excess of polyphasic potential in 6 (35.3%) patients.

**Discussion**

All patients with GBS associated with SARS-CoV-2 infection fulfilled the employed electrodiagnostic criteria for the diagnosis of AIDP, but when compared with C-AIDP showed significant differences. Notably, S-AIDP nerves showed less prolonged mean values of DML and DML less frequently reached the cut-offs for demyelination, whereas mean dCMAP duration was increased in the ulnar nerve and dCMAP duration values more frequently reached the cut-offs for demyelination. In S-AIDP nerves, DML was normal or slightly prolonged, but not reaching the employed cut-offs for demyelination, with increased dCMAP duration occurring eleven times more commonly than in C-AIDP. Increased dCMAP duration is considered a specific marker of demyelination that improves the sensitivity of criteria employed in the electrodiagnosis of AIDP [2,16]. CMAP is the summation of many MUAPs, and CMAP amplitude, duration, and morphology are mainly determined by: (1) the distribution of conduction velocities of individual axons; (2) the distance between stimulating and recording electrodes; (3) the conduction velocity of the muscle fibers; (4) phase cancellation between individual MUAPs. Normally the individual MUAP has a negative peak duration of 5–6 ms overlapping that of the negative phase of dCMAP. Indeed, with distal nerve stimulation most MUAPs arrive at the recording electrodes in phase with each other and the resulting CMAP is quite compact because of the restricted range of conduction velocities of axons (around 10 m/sec) and the short distance between the stimulating and recording electrodes. In the nerves of S-AIDP patients with normal DML and increased dCMAP duration at least some large diameter fast fibers conduct normally and the increased dCMAP duration could be explained by preferential demyelination of slower conducting nerve fibers or by conduction slowing of muscle fibers. Interestingly in critical illness myopathy (CIM), besides reduced dCMAP amplitudes, prolonged dCMAP durations (comparable to those found in S-AIDP nerves with normal or slightly prolonged DML) have been reported [1,10,11]. Reduced muscle fiber excitability can

| Table 3 | Frequency of abnormal motor conduction parameters in nerves of AIDP patients with SARS-CoV-2 infection (S-AIDP) and in control AIDP (C-AIDP). |
|---------|-------------------------------------------------------------------------------------------------|
|         | S-AIDP 103 nerves No (%) | C-AIDP 179 nerves No (%) | P       |
| Prolonged DML | 27 (26.2) | 127 (70.9) | 0.000* |
| Increased dCMAP duration | 51 (49.5) | 58 (32.4) | 0.002* |
| Increased p/d CMAP duration | 14 (13.6) | 11 (6.1) | 0.016* |
| Decreased CV | 10 (9.7) | 24 (13.4) | 0.179 |
| Prolonged F latency | 9 (8.7) | 34 (19.0) | 0.001* |
| F not recordable | 47 (45.6) | 57 (31.8) | 0.011* |
| Prolonged DML and increased dCMAP duration | 19 (18.4) | 54 (30.2) | 0.015* |
| Prolonged DML and normal dCMAP duration | 9 (8.7) | 74 (41.3) | 0.000* |
| Normal dCMAP duration | 32 (31.1) | 5 (2.8) | 0.000* |

CMAP, compound muscle action potential; CV, conduction velocity; DML, distal motor latency; d, distal; p, proximal; ; normal or slightly increased but not reaching the employed cut-offs for demyelination.

| Table 4 | Sensory action potential amplitudes and sural sparing in AIDP patients with SARS-CoV-2 infection (S-AIDP) and in control AIDP (C-AIDP). |
|---------|-------------------------------------------------------------------------------------------------|
|         | Ulnar SNAP (µV) | Sural SNAP (µV) | Sural sparing (%) |
|         | Mean (SD) [range] No | NR (%) | Reduced/NR (%) | Mean (SD) [range] No | NR (%) | Reduced/NR (%) | |
| S-AIDP | 10.9 (6.1) [9.9—25.0] 27 | 3/30 (10) | 15/30 (50) | 12.5 (7.3) [0.6—26.2] 30 | 7/37 (18.9) | 10/30 (30) | 7/23 (30.4) |
| C-AIDP | 7.4 (6.2) [1.0—23.8] 26 | 21/47 (44.7) | 41/47 (87.2) | 13.6(8.6) [3.8—38.0] 38 | 8/46 (17.4) | 13/46 (28.3) | 26/46 (56.5) |
| P t-test | 0.041* | 0.001* | 0.000* | 0.609 | 0.430 | 0.437 | 0.022* |

No, number of nerves; NR, no response; SNAP, sensory nerve action potential.
explain low CMAP amplitudes in humans with CIM and in animal models [17–19]. In an in vitro model, serum from CIM patients applied to single muscle fibers induced depolarization of resting membrane potential, reduced the action potential rise time, and increased inward sodium current peak amplitude [7]. In patients with CIM, mean muscle fiber conduction velocity was halved, the conduction velocity ratio between fastest and slowest fibers doubled, and an inverse relationship between conduction velocity of muscle fibers and CMAP durations was demonstrated [1]. It can be hypothesized that in CIM associated with sepsis and systemic inflammatory response syndrome, a depolarizing shift of muscle membrane potential, possibly caused by inflammatory cytokines, may induce sodium-channel inactivation, slowing of conduction velocity or even membrane inexcitability, and eventually muscle damage [7,8]. Some COVID-19 patients present a so-called “cytokine storm”, an uncontrolled over-production of soluble inflammatory markers which, in turn, sustains an aberrant systemic inflammatory response [13]. In the cohorts reported here, patients with S-AIDP had more frequent respiratory failure and were more frequently admitted to ICU compared to C-AIDP, probably because of summation of the effects of COVID-19 and GBS. Specifically, all 11 patients with normal or slightly prolonged DML and increased dCMAP duration in at least two nerves had pneumonia with respiratory insufficiency and 72.7% were hospitalized in ICU. We hypothesize that in these patients the increased dCMAP duration with normal or slightly prolonged DMLs indicates an additional involvement of muscle fiber excitability, similar to that described in CIM and likely due to the COVID-19 hyperinflammatory state. If increased dCMAP duration is not, as previously thought, specific of demyelination[16] but may also be due to muscle conduction slowing, it is important to establish how much this abnormality might have influenced electrodiagnosis in the S-AIDP group. As a matter of fact in three (12.5%)
patients, increased dCMAP duration in at least two nerves was decisive for the diagnosis. When the increased dCMAP durations were excluded, the electrodiagnosis changed in two patients to equivocal: in one patient who had one prolonged F wave and two slow CVs not reaching the demyelinating cut-off; in the other who had one increased p/d CMAP duration. However, in the latter patient, a control study after 17 days showed two increased p/d CMAP duration, one prolonged F wave and one slow CV confirming the AIDP diagnosis. The third patient, a 47-year-old man, had severe COVID-19 pneumonia and very high titers of IL6 (6152 pg/ml, normal <3.4) at ICU admission when severe muscle weakness was noted. Five days later, the patient was in a coma and electrophysiology showed: normal DMLs, slightly reduced dCMAP amplitudes in the ulnar (5.2 mV) and tibial (5.4 mV), increased dCMAP durations in the tibial nerves (163% and 204% ULN), three unrecordable F waves, normal ulnar and sural SNAP. EMG did not show spontaneous activity and voluntary recruitment was not possible. CSF examination was not performed because of anticoagulant therapy. The patient was treated with three courses of intravenous immunoglobulins and five plasma exchanges without any improvement and died 46 days after ICU admission. In this patient, if we exclude increased dCMAP durations, there remain absent F waves that are usually considered an expression of a proximal conduction block in the early stage of AIDP or acute motor axonal neuropathy [6,12]. However, absent F waves that re-emerged soon after a short burst of repetitive stimulation have been recently described in two patients with CIM (one with COVID-19) and thought to be due to hypo-excitability of α-motor neurons because of reduced mobility [21,29]. For the above considerations, it is likely that increased dCMAP durations and absent F waves could be alternatively explained by reduced muscle excitability due to systemic hyperinflammation and immobility. Therefore the diagnosis should be changed to that of CIM. Indeed, the frequency of unrecordable F-waves was higher in S-AIDP patients and it is conceivable that the greater disease severity and the higher ICU hospitalization rate with immobilization may at least in part contribute to F-wave absence.

This study has some limitations inherent to all studies conducted in an epidemic setting. EMG was not performed in all patients and was evaluated only qualitatively. MUAP analysis, although often difficult to accomplish in weak, sedated, ICU patients, could have helped to better assess muscular involvement. Moreover the very recently described technique to investigate the reemergence of F-wave after short burst stimulation was not employed.

Conclusions

Patients with S-AIDP frequently present increased dCMAP durations and absent F waves.

Increased dCMAP duration, thought to be specific for acquired demyelinating neuropathies, can be also found in CIM; at least in some S-AIDP patients, this can be due to muscle fiber conduction slowing because of the hyperinflammatory state of COVID-19.

Unrecordable F waves does not necessarily imply proximal conduction failure in severe COVID-19 patients and may be due to prolonged immobilization because of ICU stay with consequent α-motor neuron hypoexcitability.

The above considerations should be taken into account when examining patients with COVID-19 and weakness, to avoid misdiagnoses.

Declarations of interest

None declared.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for profit sector.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.neucli.2021.02.001.

Declaration of Competing Interest

The authors report no declarations of interest.

References

[1] Allen DC, Arunachalam R, Mills KR. Critical illness myopathy: further evidence from muscle fiber excitability studies of an acquired channelopathy. Muscle Nerve 2008;37:14–22.
[2] Cleland JC, Malik K, Thaisetawatuki P, Hermann DN, Logigan EL. Acute inflammatory demyelinating polyneuropathy: contribution of a dispersed distal compound muscle action potential to electrodiagnosis. Muscle Nerve 2006;33:771–7.
[3] Derksen A, Ritter C, Ahtar P, Kieseier BC, Mancias P, Hartung HP, et al. Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics. Muscle Nerve 2014;50:780–4.
[4] Ellul MA, Benjamin L, Singh B, Lart S, Michael BD, Eanston A, et al. Neurological association of COVID-19. Lancet Neurol 2020;30:221–30, http://dx.doi.org/10.1016/S1474-4422(20).
[5] Filosto M, Cotti Piccinnelli S, Gazzina S, Foresti C, Frigeni B, Savalli C, et al. Guillain-Barré Syndrome and COVID-19: an observational multicenter study from two Italian hot-spot regions. J Neurol Neurosurg Psychiatry 2020, http://dx.doi.org/10.1136/jnnp-2020.324837. Nov 6: jnnp-2020-324837.
[6] Fisher MA. AANEM Minimonograph #13: H reflex and F waves: physiology and clinical indications. Muscle Nerve 1992;15:1223–33.
[7] Friedrich O, Hund E, Weber C, Hacke W, Fink RH. Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle. J Neurol 2004;251:53–65.
[8] Friedrich O, Reid MB, Van den Berge G, Vanheuven J, Hermans G, Rich MM, et al. The Sick and the Weak: neuropathies/myopathies in the critically ill. Physiol Rev 2015;95:1025–109.
[9] Geisser S. Modes of parametric statistical inference. Hoboken: John Wiley & Sons; 2006.
[10] Goodman BP, Harper CM, Boon AJ. Prolonged Compound Muscle Action Potential Duration in critical illness myopathy. Muscle Nerve 2009;40:1040–2.
[11] Kramer CL, Boon AJ, Harper CM, Goodman BP. Compound muscle action potential in critical illness neuromyopathy. Muscle Nerve 2018;57:395–400.

[12] Kuwabara S, Ogawara K, Mizobuchi K, Koga M, Mori M, Hattori T, et al. Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barré syndrome with anti-ganglioside antibodies. J Neurol Neurosurg Psychiatry 2000;68:191–5.

[13] Mangalmurti N, Hunter CA. Cytokine storms: understanding COVID-19. Immunity 2020;53:19–25.

[14] Mitsuma S, Van den Bergh P, Rajabally YA, Van Parijs V, Martin-Lamb D, Sonoo M, et al. Effects of low frequency filtering on distal compound muscle action potential duration for diagnosis of CIDP: A Japanese European multicenter prospective study. Clin Neurophysiol 2015;126:1805–10.

[15] Pesarin F, Salmaso L. Permutation Tests for Complex Data. Theory, applications and software. Chichester: John Wiley & Sons; 2010.

[16] Rajabally YA, Nicolas GN. Value of distal compound muscle action potential duration Prolongation in acute inflammatory demyelinating polyneuropathy: a European perspective. Muscle Nerve 2011;43:751–5.

[17] Rich MM, Teener JW, Raps EC, Schotland DL, Bird SJ. Muscle is electrically inexcitable in Acute quadriplegic myopathy. Neurology 1996;46:731–6.

[18] Rich MM, Pinter MJ, Kramer SD, Barchi RL. Loss of electrical excitability in an animal model of acute quadriplegic myopathy. Ann Neurol 1998;43:171–9.

[19] Rich MM, Pinter MJ. Crucial role of sodium channel fast inactivation in muscle fiber inexcitability in a rat model of critical illness myopathy. J Physiol 2003;547:555–66.

[20] Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011;29:599–612.

[21] Tankisi H, Tankisi A, Harbo T, Markvardsen LK, Andersen H, Pedersen TH. Critical illness myopathy as a consequence of Covid-19 infection. Clin Neurophysiol 2020;131:1931–2.

[22] Uncini A, Ippoliti L, Shahrizaila N, Sekiguchi Y, Kuwabara S. Optimizing the electrodiagnostic accuracy in Guillain-Barré syndrome subtypes: Criteria sets and sparse linear discriminant analysis. Clin Neurophysiol 2017;128:1176–83.

[23] Uncini A, González-Bravo DC, Acosta-Ampudia YY, Ojeda EC, Rodriguez Y, Monsalve DM, et al. Clinical and nerve conduction features in Guillain-Barré syndrome associated with zika virus infection in Cúcuta, Colombia. Eur J Neurol 2018;25:644–50.

[24] Uncini A, Kuwabara S. The electrodiagnosis of Guillain-Barré syndrome: where do we stand? Clin Neurophysiol 2018;129:2586–93.

[25] Uncini A, Vallat J-M, Jacobs B. Guillain Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry 2020, http://dx.doi.org/10.1136/jnnp-2020-324491.

[26] Wakerley B, Uncini A, Yuki N, GBS Classification Group. Guillain-Barré and Miller Fisher syndrome—new diagnostic classification. Nat Rev Neurol 2014;10:537–44.

[27] WHOa. Coronavirus disease 2019 (COVID-19): situation report, 61. Geneva: World Health Organization, 2020.

[28] WHOb. Laboratory testing for coronavirus disease 2019 (2019-nCoV) in suspected human cases. Geneva: World Health Organization, 2020.

[29] Zimnowodzki S, Butrum M, Kimura J, Stalber E, Mahajan S, Gao L. Emergence of F-waves after repetitive nerve stimulation. Clin Neurophysiol Pract 2020;5:100–3.